Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides

Desheva, Yulia; Leontieva, Galina; Kramskaya, Tatiana; Smolonogina, Tatiana; Grabovskaya, K. B.; Landgraf, Galina O.; Карев, В. Е.; Suvorov, Alexander; Rudenko, Larisa

doi:10.1177/1178122x17710949

Cited by 5 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this purpose, we used mice, which are a widely used experimental model in the study of GBS infection [ 25 , 26 ]. In present study as well as in our early tests of the protective efficacy of recombinant GBS proteins the experiments were carried out on the model of outbred mice [ 27 – 29 ].…”

Section: Discussionmentioning

confidence: 99%

Development of experimental GBS vaccine for mucosal immunization

Gupalova¹,

Leontieva²,

Kramskaya³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

Streptococcus agalactiae, or group B streptococcus (GBS), is an important pathogen as it is the leading cause of neonatal deaths due to sepsis, meningitis or bacterial pneumonia. Although the development of an effective and safe GBS vaccine is on the agenda of many research labs, there is no GBS vaccine on the market yet. In the present study we attempted to engineer a live vaccine strain based on Bac, a surface protein of GBS, incorporated into a surface fimbrial protein of probiotic Enterococcus. The resulting strain induced specific systemic and local immune responses in mice and provided protection against GBS when administered via the intranasal, oral or intravaginal immunization routes.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of experimental GBS vaccine for mucosal immunization

Gupalova¹,

Leontieva²,

Kramskaya³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The LAIV of H7N3 subtype raised serum antibodies not only against the homologous virus but also against H7N9, which possessed the difference of 3% in the HA amino acid sequence. In the sera from mice double-vaccinated with H7N3 LAIV, serum HI titers against H7N9 were 20-40 times higher than against H7N3 (P < 0.05) [56]. At the same time, local IgA levels were higher against homologous H7N3 compared with H7N9 after vaccination with LAIV.…”

Section: Immunogenicity and Cross-protection In Micementioning

confidence: 88%

“…The ability of LAIV to induce antibodies not only to the homologous variant subtype but also to cross-reacting antibodies to antigenically different variants including HP variants was shown in several mouse studies [50][51][52][54][55][56].…”

Section: Immunogenicity and Cross-protection In Micementioning

confidence: 99%

Preparing Live Influenza Vaccines against Potential Pandemic Influenza Using Nonpathogenic Avian Influenza Viruses and Cold-Adapted Master Donor Strain

Desheva¹

2018

Influenza - Therapeutics and Challenges

View full text Add to dashboard Cite

As part of an influenza pandemic preparedness program, the WHO analyzes a range of potentially pandemic influenza viruses for appropriate vaccines development. Several vaccine candidates were prepared using classical genetic reassortment, with the coldadapted A/Leningrad/134/17/57(H2N2) (Len/17) master donor strain (MDS) which is licensed in the Russia for the live influenza vaccine (LAIV) strains type A production for adults and children. The nonpathogenic avian viruses of different subtypes were used for reassortant vaccine strains preparation. All vaccine candidates demonstrated a high reproductive capacity and cold-adapted (ca-) phenotype in chick embryos. In mice, the LAIV of H5N2, H7N3, and H9N2 subtypes provided protection against infection with distant influenza viruses. The immunogenicity and protective efficacy of H7N3 LAIV was also demonstrated in ferrets. The H5N2 and H7N3 vaccine candidates demonstrated the inability to reproduce in chickens, which confirms the safety of their use in areas with highly developed agriculture. When tested in clinical trials, vaccine strains of H5N2 and H7N3 subtypes induce the conversions of antibodies homologous and antigenically distant variants. The use of LAIV can be effective against highly pathogenic influenza viruses even in the case of incomplete antigenic correspondence between the vaccine strain and the infectious virus.

show abstract

“…For the prevention of respiratory infections, it is important to develop mucosal vaccines to stimulate not only systemic but also local humoral immunity. Previously, the immunogenicity, including local IgA formation, and protective efficacy of recombinant group B streptococcus (GBS) proteins in combination with LAIV, were demonstrated in mouse experiments after intranasal administration [2]. The protective effect of associated vaccination against double influenza and GBS infections correlated with serum and local antibody response against vaccine compounds and increased expression of type II interferon – interferon-gamma – in the lungs of mice [2].…”

Section: Introductionmentioning

confidence: 99%

“…Previously, the immunogenicity, including local IgA formation, and protective efficacy of recombinant group B streptococcus (GBS) proteins in combination with LAIV, were demonstrated in mouse experiments after intranasal administration [2]. The protective effect of associated vaccination against double influenza and GBS infections correlated with serum and local antibody response against vaccine compounds and increased expression of type II interferon – interferon-gamma – in the lungs of mice [2]. Unlike the adaptive immune response, which is very specific, the agents of innate immunity provide protection against a wide range of pathogens.…”

Section: Introductionmentioning

confidence: 99%

Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection

Desheva

Leontieva

Kramskaya

et al. 2019

Heliyon

View full text Add to dashboard Cite

We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20% of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs.Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway.

show abstract

Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides

Cited by 5 publications

References 39 publications

Development of experimental GBS vaccine for mucosal immunization

Development of experimental GBS vaccine for mucosal immunization

Preparing Live Influenza Vaccines against Potential Pandemic Influenza Using Nonpathogenic Avian Influenza Viruses and Cold-Adapted Master Donor Strain

Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection

Contact Info

Product

Resources

About